Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)

NCT03217903 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT03217903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03217903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)
Lead sponsor
Central Hospital, Nancy, France
Phase
Not applicable
Overall status
Unknown status
Start date
October 12, 2017
Completion date
January 1, 2022
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk myelodysplastic syndromes with excess blasts